Andrew Schorr: Hello and welcome once again to Patient Power, sponsored by the Seattle Cancer Care Alliance. I'm Andrew Schorr.
|
|
- Julianna Williams
- 5 years ago
- Views:
Transcription
1 The Latest in Gynecological Cancers Webcast May 21, 2008 Banjamin Greer, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That s how you ll get care that s most appropriate for you. Introduction Hello and welcome once again to Patient Power, sponsored by the Seattle Cancer Care Alliance. I'm Andrew Schorr. One of the areas that has been daunting, if you will, in some parts of it is gynecologic cancers. Ovarian cancer has been such a devastating diagnosis for women because it's usually discovered late and often leads to a high mortality rate. There are other gynecologic cancers too, cervical cancer and endometrial cancer. We're going to talk about that today with the director of the gynecologic oncology program at the Seattle Cancer Care Alliance and get an update for women and families touched by any of these conditions and also talk about what can we do nowadays about prevention and where are we with research and doing better in the treatment of these illnesses. With me is Benjamin Greer. Dr. Greer is the director of the gynecologic oncology program at the Seattle Cancer Care Alliance. He's also a professor in the department of obstetrics and gynecology at the University of Washington. Dr. Greer, welcome back to Patient Power. Andrew, thanks for having me back. It's nice to chat with you again. Dr. Greer, so let's start first of all with the deadliest of all of these cancers, ovarian cancer. Women worry about this and often someone has a friend and they're angry it's discovered late, and the fear has been there's not much that can be done. So first of all, why is ovarian cancer typically discovered late? What's been the problem there? And do we have any clues that might help us discover it earlier when there's more you can do? Discovering Cancer Early Well, the main reason that ovarian cancer is diagnosed late is we don't have any tests that can easily predict the pre-onset phase of ovarian cancer. Consequently, the majority of patients have spread from the ovary in the abdomen or possibly to 1
2 have fluid on their lungs with malignant cells so they are stage III or stage IV cancer when diagnosed. Where are we with what we can do in that situation? And maybe along the way help us understand, what are the diagnostics you do these days to just understand how far the cancer has advanced? A couple of things. We Hutchinson center have an ovarian spore project that has been ongoing for over a decade looking at ways to try and diagnose ovarian cancer through screening means using blood tests as a marker. Unfortunately to date we have not been successful in identifying an appropriate test. The other piece of information that is being developed is a symptom index that has been led by the division of gyn oncology. Basically this is an attempt to look at a woman's symptoms that usually are abdominal complaints based on bloating and change in GI, gastrointestinal function that can predict whether or not an individual may be at risk for ovarian cancer. Basically women who have chronic gastrointestinal complaints probably aren't at risk, but someone that has more recent onset of complaints may be someone with ovarian cancer and need to be evaluated. So when we talked about it being discovered often at stage III or stage IV, what do you do at that time? Is that a surgical approach or surgical and chemotherapy? What are you doing now at the SCCA? Usually when someone is diagnosed that they have either a palpable pelvic mass or they've had a CT scan that demonstrates that there is either a pelvic mass with ascites, which is fluid in the abdomen, and evidence of involvement of the omentum, which is the fatty pad in the abdomen that we have, and this is an indication for a surgical approach. The main first step in ovarian cancer is what we call tumor reductive surgery where one tries to remove the uterus tubes, ovaries and as much of the tumor that is resectable ideally to resect the disease down to individual aggregates that are one centimeter or less. A centimeter is a little less than a half an inch in diameter. Chemotherapy is then the next step, which usually is a combination of a drug called Taxol and a drug called carboplatin, which are given every three weeks for six cycles to evaluate at the end of that time the status of their disease. The majority of women will respond to surgery plus chemotherapy. Unfortunately there are still a fairly high recurrence rate even after initial remission of their disease. 2
3 So where are we with trying new things? We've heard about these antiangiogenesis drugs trying to stop the blood supply to the tumor cells. Where are we with that and some drugs maybe that are either totally in research now or drugs that have been approved for other cancers? The antiangiogenesis drug called Avastin was in a gynecologic oncology trial in patients that had failed other regimens with a good response rate. That was published last year. The ongoing gynecologic oncology trial is a trial that has Taxol and carboplatin as one arm; Taxol, carboplatin plus Avastin for six cycles; and then there is a third arm that's Taxol, carboplatin and Avastin for six cycles; and then the Avastin is given on as a maintenance drug. So this is really testing two different premises. One is that Avastin may improve the outcome over just Taxol and carboplatin and then testing the idea does maintenance therapy have benefit in this group of patients. This is an ongoing study. It's a randomized controlled trial. You have at the Seattle Cancer Care Alliance of course many clinical trials that are under way including in gynecologic cancers. Where are you with other kinds of drugs that are in development maybe following the same idea of antiangiogenesis? Drugs Developments for Gynecological Cancers There is a large number of antiangiogenesis drugs that are in development, and we have several of those that have been evaluated at the Seattle Cancer Care Alliance. Some of these studies are in patients that have failed other regimens, other drug regimens, and sometimes it's the second or third failed regimen that these patients are tried on. Obviously any of these studies, patients have to have certain eligibility criteria to participate in these studies, and it requires that they be evaluated and then potentially consented and treated. The other drugs that have shown activity in ovarian cancer are topotecan, Doxil, which is a liposomal Adriamycin product, and then Gemzar or gemcitabine. These have recently been tested in a variety of combinations with Taxol and carboplatin as first line agents, and preliminary results of that gynecologic oncology trial doesn't demonstrate any advantage of these agents over Taxol and carboplatin alone. They are important in terms of women who fail or relapse after being initially treated with Taxol and carboplatin. They have different toxicity profiles depending on the patient, and their medical condition selection is kind of individualized for the given patient. Well, I'm noticing as I look on the SCCA website, which is terrific, where you can look by cancer type and what trials may be available, your name as principal investigator is there with numerous ones. So if someone comes to you at the Seattle Cancer Care Alliance and, let's say, they're diagnosed with ovarian cancer, 3
4 it's discovered late, how you do you and that woman look at, say, what are the standard therapies you have and is there a clinical trial that maybe we should put on the table for discussion of whether this might be an opportunity for you? How do you have that discussion? What guidance would you give us? Well, I think first I just want to point out the philosophical issue that I have with patients. Most patients that get diagnosed with ovarian cancer, either they or their friends and family go to the internet and get very discouraged about potential outcome. And I always tell patients that the only person that really counts is what happens to that individual, and that you don't know who is going to win until you play, and the object is to try and get the best response and the best outcome for the patient. We try to as we see patients evaluate them for the possibility of a clinical trial, and if they are eligible for a clinical trial is to offer the trial to the patient and sit down and thoroughly go over all the details of what it entails to be part of a clinical trial, and if they accept obviously we then carry forward with the trial. There is oftentimes reasons why patients cannot participate in trials. One of the examples would be some woman who may have had a breast cancer two years ago. Because of the rules of the trial they wouldn't be eligible to participate in a clinical trial, and those individuals would be treated with standard combinations of drug depending on the site of disease. As we look overall with ovarian cancer then, how do you feel about things? For instance we're starting to hear about trying to identify genes that may be at risk. My producer was mentioning to me there has been talk about the loss of the GPC3 gene and maybe there was a connection to ovarian cancer. We're learning who may be at risk so that people can have surveillance and hopefully we don't get to the situation where it's discovered late. The genetic literature is quickly exploding in terms of new information that could be applied to patients that potentially are at risk. With the completion of the genome project it's provided the alphabet, if you will, that can look at different genes and then what are at risk. In ovarian cancer probably the BRCA1 and 2 story is the best story that's available, and the patients that have those genes are at risk for ovarian cancer as well as breast cancer. Well, follow-up then, you see women who are diagnosed with ovarian cancer. Are they typically worked up genetically to see might there be a reason for testing for BRCA1 and 2 and if so then have a consultation with their family? When we see patients we try to investigate their cancer history within the family and if they are looked to potentially be at risk for a BRCA1 or 2 mutation is that we 4
5 refer them to the high-risk breast and ovarian cancer clinic at the SCCA. That clinic has genetic counselors that do prescreening and take an extensive family pedigree, and then the patient is seen and then counseled about genetic testing. The major kind of things that we look for are other first-degree relatives that have ovarian cancer and then also women who are of Jewish heritage also are at risk, especially the Ashkenazi Jewish population. The patient that is at risk is to have the individual who has the disease be evaluated for the genetic abnormality, and if they're negative then that would mean that their offspring would not be at risk. If they are positive then there's the possibility that children or grandchildren of that individual may be at risk. One has to also remember that the BRCA1 gene can be transmitted genetically through a male child of the patient, and so this needs to be kept in mind when looking at this genetic risk. Wow. Lots to talk about. So is there anything we can do besides ultimately genetic evaluation to prevent ovarian cancer? We have people that have genetic abnormalities that we offer prophylactic removal of both the ovary and fallopian tube. We identified as have other centers that some ovarian cancers may actually begin in the fallopian tube, and in our experience we have discovered early fallopian tube cancers during prophylactic surgery. There are other things. Women who have been on oral contraceptives has a protective effect of developing ovarian cancer. In addition women that have more I don't know how to describe it you know, have multiple children are at less risk for ovarian cancer. The concept behind ovarian cancer revolves around ovulation potentially as an inciting factor in the ovarian cancer process. Most of the time we often talk about the avian model where if you take a hen and let them ovulate for their lifetime and then at year seven sacrifice the hen and do an autopsy that 60 percent of those will have an ovarian cancer-like process going on. So in other words, fewer periods as you'd have when you're pregnant would be better then, it sounds like. That's correct. Wow. Well, a lot more to learn from that. Well, I wish you well with the progress in ovarian cancer with its high mortality rate, although I hear you say clearly that every woman needs to understand her situation as a unique one and that's the discussion they have with specialists like you as they seek treatment. Let's talk about a couple of other gynecologic cancers in the time that's left. Now, in cervical cancer we have made progress, haven't we? 5
6 Cervical cancer, the number of cervix cancers per year is below 10,000 annually at this time. This is predominantly due to cytologic screening with the pap smear or cervical cytology using a liquid-based cytology method which is probably the most common. So we have and that pre-invasive cancer lesions are identified and can be treated and therefore reduce the risk of the patient. One of the major advances in treating advanced cervical cancer is the addition of chemotherapy during the radiation. There was an NCI alert several years ago citing five different randomized controlled trials demonstrating survival advantage by combining chemotherapy and radiation together. Ordinarily the radiation is given daily Monday through Friday and one of the days the patient receives chemotherapy, which is usually cisplatin as a single agent at a fairly low dose, and this has improved the outcome in cervical cancer patients. HPV Vaccine and Gynecological Cancers Now, what about the vaccine, the HPV vaccine? Where does that come in in helping our daughters and young women? The vaccine I think is a great advance. The one that is currently on the market is what we call a quadrant valent vaccine, which is against HPV virus number six, 11, 16 and and 18 are the ones that are associated with cervical cancer risk. Six and 11 can cause other noncancers, GYN complaints, which obviously the vaccine can't do that. And the recommendations are for women between 12 and 26 to potentially be vaccinated. This, as much as I think it's going to be a great advance, it's going to be probably 15, 20 years or more before we see the total impact of the vaccine because women who are already at risk would not be candidates for the vaccine. The other is that we are recommending, at least until we learn more, not to change screening practices in women that get the vaccine because only about 70 percent of cervical cancers are going to be prevented by the vaccine so that there still is a risk of developing cervical cancer that's probably due to some other HPV viral environment that we don't have vaccines for at this time. For where the vaccine is effective though, if a woman has already had sexual relations, been exposed to HPV, which I understand is in so many of us, then would the vaccine work? Or would you have to receive the vaccine before any exposure? The ideal patient is someone who has not been infected by HPV viruses. There's ongoing evaluations of women who may have had an HPV infection and to see what the protection of the vaccines will be, but those are ongoing studies. The other 6
7 studies that are ongoing is since we think that most HPV infections are sexually transmitted there is ongoing HPV vaccine studies in males trying to see if that part of the cohort can be the incidence be reduced. Okay. Well, still a lot to learn. One other gynecologic cancer I wanted to talk about was endometrial, which I understand out of the 78,000 annual gynecologic cancers that are diagnosed in the US endometrial is the most common. Where are we now in improving our therapy there? Improving Therapies for Endometrial Cancer Endometrial cancer is usually in an older population, and usually you have bleeding as a sign of potential cancer and can be evaluated by having an endometrial biopsy, which can be done as an office procedure. And if the diagnosis of endometrial cancer is established then we recommend primary surgery, which would include the removal of the uterus, tubes, ovaries, doing what we call a peritoneal cytology, which is obtaining fluid from the abdominal cavity and doing like a pap smear on it. In addition is to do a lymph node dissection of the pelvis and periaortic area to determine if the cancer has spread to the lymph nodes. After all this information is gathered I look at this as an assessment of the various risk factors, and depending on the risk factors the patient may not require any additional treatment. Fortunately, 85 percent of patients who have endometrial cancer fall into what I call a low-risk group and just require surveillance with pap smears and pelvic exams. The other 15 percent require additional treatment and sometimes it's local radiation to the vaginal apex or radiation and/or chemotherapy for management of disease that is beyond the confines of the uterus. There has been some changing philosophies including more chemotherapy regimens along with radiation or even just chemotherapy as the only adjuvant treatment. Dr. Greer, I know we're talking about different sites, endometrial, cervical, ovarian and then maybe different sub types as we learn more about the biology of each woman's cancer, but in your field of gynecologic oncology how are we doing? I mean, there are some areas of cancer we feel, whoa, things are changing dramatically and others where it's been slower. How do you feel about how we're doing and what hope we can offer women today and the importance understanding their own individual situation? In terms of the field of oncology I think gyn oncology is doing very well. More than 70 percent of the patients that have gynecologic cancers can be cured. And we spoke earlier about ovarian cancer and it not being as well controlled because of its advanced stage when diagnosed, but I think overall women with gynecologic cancers have a good outcome in terms of the outlook for their diseases. 7
8 And as far as research, since you're at a research institution as you look at what's going on in the labs, are you encouraged? Do you see a lot of promise there? We've touched on the genetic aspect of some of these diseases, and I think as the field is moving rapidly I think genetic evaluations may become a part of the screening process. We just are completing in the Gynecologic Oncology Group a study looking at molecular profiling of endometrial cancer, which is trying to look at biochemical changes in the cancer cells themselves to try to evaluate outcome and see if we can do predictions of outcome based on this information. This study has not been completed, but I think it will provide us with valuable information. Molecular evaluation in breast cancer outcomes has been significant in terms of treating breast cancer, and I think it will be similar in endometrial cancer when we complete this study. There's some neat work going on in your institution. I know we just did a program with Dr. Evan Yu about cancer biomarkers, and as you're saying like in ovarian you don't have the perfect one yet, but, boy, it would be great if that could be developed. And then also the molecular, understanding you're talking about as now in breast cancer understanding which woman will be a candidate for which treatments, chemotherapies, etc., and where it's likely to respond. That would be so helpful, too. Well, Dr. Benjamin Greer, director of gynecologic oncology at the Seattle Cancer Care Alliance, and professor in the department of obstetrics and gynecology at the University of Washington, thank you so much for being with us and helping us understand an update. And also it always underscores for me when I talk to you, sir, of how important it is and I would really mention this in this case for women if you're diagnosed with one of these illnesses I really would recommend a consultation with a sub specialist such as Dr. Greer and what they offer at the Seattle Cancer Care Alliance. It really can give you the best knowledge of what may apply to your specific situation today and also is there research going on that might be helpful to you as well. Dr. Greer, thanks for being with us. Andrew, thanks. It's been a pleasure. 8
9 And I will just mention that our next program will be with Dr. Mike Mulligan, who has been on Patient Power as well before, just like Dr. Greer. And we'll be discussing minimally invasive video assisted thoracic surgery or VAT surgery for people afflicted with lung cancer. Thank you so much for joining us. As always, knowledge can be the best medicine of all. For the Seattle Cancer Care Alliance, I'm Andrew Schorr. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient Power. Our discussions are not a substitute for seeking medical advice or care from your own doctor. That s how you ll get care that s most appropriate for you. 9
Breast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Introduction
Breast Cancer Imaging Webcast October 21, 2009 Peter Eby, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or
More informationDr. Gopal, are you encouraged in the direction of where research is headed and its benefit for patients?
Targeting the Tumor in Lymphoma July 8, 2009 Ajay Gopal Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff or Patient
More informationFine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013
Fine-Tuning Immunotherapy to Treat Prostate Cancer Recorded on: April 24, 2013 John Corman, M.D. Medical Director, Floyd & Delores Jones Cancer Institute at Virginia Mason Virginia Mason Medical Center
More informationTracking Genetic-Based Treatment Options for Inflammatory Bowel Disease
Tracking Genetic-Based Treatment Options for Inflammatory Bowel Disease Recorded on: June 25, 2013 Melvin Heyman, M.D. Chief of Pediatric Gastroenterology UCSF Medical Center Please remember the opinions
More informationMinimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients
Minimally Invasive Surgery Offers Promise for Pancreatic Cancer Patients Recorded on: August 1, 2012 Venu Pillarisetty, M.D. Surgical Oncologist Seattle Cancer Care Alliance Please remember the opinions
More information4:00 into mp3 file Huang_342831_5_v1.mp3
Support for Yale Cancer Answers comes from AstraZeneca, providing important treatment options for women living with advanced ovarian cancer. Learn more at astrazeneca-us.com. Welcome to Yale Cancer Answers
More informationHello and welcome to Patient Power sponsored by Northwestern Memorial Hospital. I'm Andrew Schorr.
Brain Tumor Clinical Trials Webcast November 22, 2011 Sean Grimm, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Northwestern Memorial Hospital, its medical
More informationWe know that treatments are now targeting genes, but does genetics play a bigger role in cancer outside of that?
Welcome to the 3Ps of Cancer podcast, where we'll discuss prevention, preparedness, and progress in cancer treatments and research. Brought to you by the University of Michigan Rogel Cancer Center. I'm
More informationPROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO
PROSTATE CANCER SCREENING SHARED DECISION MAKING VIDEO 1 00:00:00,067 --> 00:00:10,968 2 00:00:10,968 --> 00:00:12,701 So, you were given a decision aid sheet 3 00:00:12,701 --> 00:00:14,567 about prostate
More informationHello and welcome to Patient Power sponsored by UW Medicine Health System. I'm Andrew Schorr
Advanced Techniques for Treating Liver Tumors Webcast James O. Park, M.D. Veena Shankaran, M.D. Raymond S.W. Yeung, M.D., FRCS(C), FACS Derek Epps November 28, 2011 Please remember the opinions expressed
More informationTargeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr
Targeted Therapies in Breast Cancer Webcast October 24, 2007 Julie Gralow, M.D. Hosted By Andrew Schorr Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationHereditary Cancer Syndromes and the Obstetrician/Gynecologist
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/hereditary-cancer-syndromes-and-theobstetriciangynecologist/6990/
More informationConversations: Let s Talk About Bladder Cancer
Understanding Biomarkers Matt Gaslky, MD, Professor of Medicine Icahn School of Medicine at Mount Sinai Piyush Agarwal, MD, Head, Bladder Cancer Section Urological Oncology Branch, National Cancer Institute
More informationBreakthrough Understanding in Pancreatic Cancer Therapy
Breakthrough Understanding in Pancreatic Cancer Therapy Recorded on: May 28, 2013 Sunil R. Hingorani, M.D., Ph.D. Associate Member Fred Hutchinson Cancer Research Center Please remember the opinions expressed
More informationDebulking Surgery and HIPC to Treat Ovarian Cancer
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/debulking-surgery-and-hipc-to-treat-ovariancancer/3690/
More informationBenefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm. Introduction
Benefits of Survivorship Treatment Care Plans Webcast May 13, 2009 Scott Baker, M.D., M.S. Donald Wilhelm Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More informationDefeating Colon Cancer with Surgery
Defeating Colon Cancer with Surgery Recorded on: September 19, 2012 Alessandro Fichera, M.D. Director, Colorectal Surgical Oncology Program, Seattle Cancer Care Alliance Please remember the opinions expressed
More informationWhat You Need to Know About Ovarian Cancer
What You Need to Know About Ovarian Cancer About Us The Rhode Island Ovarian Cancer Alliance (RIOCA) was formed in honor and memory of Jessica Morris. Jessica was diagnosed with Stage IIIC Ovarian Cancer
More informationOne of the areas where it's certainly made it difference is with the transplantation of the liver. Dr. Roberts thinks so much for joining us.
Benefits and Risks of Living Donor Liver Transplant Webcast May 28, 2008 John Roberts, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationDr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014
Patient Power Knowledge. Confidence. Hope. Dr. Michael Keating: My Hopes for the Future of CLL Treatment Recorded on December 8, 2014 Michael Keating, MB, BS Professor of Medicine, Department of Leukemia
More informationWhat is ovarian cancer?
What is ovarian cancer? Ovarian cancer is a type of cancer that forms in tissues of the ovary. Most ovarian cancers are either ovarian epithelial cancers (cancer that begins in the cells on the surface
More informationDr. Coakley, so virtual colonoscopy, what is it? Is it a CT exam exactly?
Virtual Colonoscopy Webcast January 26, 2009 Fergus Coakley, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationSurgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland. Introduction
Surgical Options for Breast Cancer October 28, 2009 Kristine Calhoun, M.D. Suzie Hagerland Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance,
More informationNeo-adjuvant Therapy and Dynamic Imaging for Breast Cancer Webcast November 12, 2008 Jennifer Specht, M.D. Janelle Sabol
Neo-adjuvant Therapy and Dynamic Imaging for Breast Cancer Webcast November 12, 2008 Jennifer Specht, M.D. Janelle Sabol Please remember the opinions expressed on Patient Power are not necessarily the
More informationLiving With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel. Steve s Story
Living With Myeloma Webcast April 7, 2010 Tanya Wahl, M.D. Steve Henkel Please remember the opinions expressed on Patient Power are not necessarily the views of our sponsors, partners or Patient Power.
More informationAdvances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson. Introduction
Advances in Pediatric Bone Marrow Transplant Webcast March 4, 2011 Scott Baker, M.D., M.S. Anna Robinson Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle
More information--- or not, and do we need to come up with newer strategies for ovarian cancer screening.
My name is Dr. Karen Lu and I am a Professor of Gynecologic Oncology at the University of Texas MD Anderson Cancer Center. I also serve as Co-Medical Director for Clinical Cancer Genetics. I m going to
More information(WG Whitfield Growden, MD; DR Diane Redington, CRNP)
2795 Estates Drive Park City, UT 84060 TRANSCRIPT FOR VIDEO #4: D IAGNOSIS AND TREATMENT OF GYN CARCINOSARCOMA WITH DR. WHITFIELD GROWDEN Interview, Massachusetts General Hospital January 5, 2017 Produced
More informationSurgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte. Mike s Story
Surgical Treatment For Prostate Cancer Webcast May 6, 2010 John W. Davis, M.D., F.A.C.S. Mike Whyte Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson
More informationX-Plain Ovarian Cancer Reference Summary
X-Plain Ovarian Cancer Reference Summary Introduction Ovarian cancer is fairly rare. Ovarian cancer usually occurs in women who are over 50 years old and it may sometimes be hereditary. This reference
More informationA Case Review: Treatment-Naïve Patient with Head and Neck Cancer
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThe Latest in Non-Hodgkin Lymphoma News From ASCO
Patient Power Knowledge. Confidence. Hope. The Latest in Non-Hodgkin Lymphoma News From ASCO John Leonard, MD Associate Dean for Clinical Research Weill Cornell Medical College Please remember the opinions
More informationPap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed???
Pap Smears Pelvic Examinations Well Woman Examinations. When should you have them performed??? Arlene Evans-DeBeverly, PA-C Copyright 2012 There are always ongoing changes in gynecology, including the
More informationCognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Introduction
Cognitive Challenges After Hormone Therapy August 26, 2009 Webcast Monique Cherrier, Ph.D. Celestia Higano, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of
More informationColon Cancer Screening Webcast April 23, 2008 William Grady, M.D. Introduction
Colon Cancer Screening Webcast April 23, 2008 William Grady, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care Alliance, its medical staff
More informationAndrew Schorr: And you're a retired businessman. Tell us about this diagnosis. What was going on for you that suddenly you were sick? What happened?
Advances in the Treatment of Stomach Cancer Webcast August 5, 2008 Linus Ho, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationPrevention, Diagnosis and Treatment of Gynecologic Cancers
Prevention, Diagnosis and Treatment of Gynecologic Cancers Jubilee Brown MD and Pamela T. Soliman MD, MPH Department of Gynecologic Oncology and Reproductive Medicine University of Texas MD Anderson Cancer
More informationUnraveling Recent Cervical Cancer Screening Updates and the Impact on Your Practice
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationLet me introduce you to her. That s Barbara Scribner who joins us from Kent, Washington. Barbara, thank you so much for joining us.
Lung Cancer: Detection and Early Intervention Webcast November 30, 2009 Douglas E. Wood, M.D. Jason Chien, M.D., M.S. Barbara Scribner Please remember the opinions expressed on Patient Power are not necessarily
More informationSection 4 Decision-making
Decision-making : Decision-making Summary Conversations about treatments Participants were asked to describe the conversation that they had with the clinician about treatment at diagnosis. The most common
More informationHighlighting Clinical Trials Muscle Invasive Bladder Cancer
Highlighting Clinical Trials Muscle Invasive Bladder Cancer Part I: The Basics of MIBC Clinical Trials June 19, 2018 Presented by: Dr. Peter Black is a urologic oncologist at Vancouver General Hospital,
More informationHIV Housing Care Continuum Webinar 1 August 3, 2016
Page 1 HIV Housing Care Continuum August 3, 2016 Rita Flegel: Hello and welcome. I'm Rita Flegel, the Director of HUD's Office of HIV/AIDS Housing. And presenting with me today is Amy Palilonis also from
More informationRon: Yeah. Yeah. I screwed you up on your ages, but I was actually 54 when I was diagnosed, but, yes, that is right. I was diagnosed with that.
Cancer Biomarkers - Individualizing Cancer Care Webcast May 5, 2008 Evan Yu, M.D. Ron Swenson Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I'm Andrew Schorr.
Managing Pain from Shingles Webcast August 22, 2011 George Pasvankas, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff
More informationMarty: I had my physical in 2006, and my physician said that I had myelofibrosis and said I had three to five years to live.
Advances in the Treatment of Myeloproliferative Disorders Webcast April 28, 2009 Srdan Verstovsek, M.D., Ph.D. Marty Prager Please remember the opinions expressed on Patient Power are not necessarily the
More information6 Week Course Agenda. Today s Agenda. Ovarian Cancer: Risk Factors. Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention
6 Week Course Agenda Winning the War 11/30/2016 on Women s Cancer Gynecologic Cancer Prevention Lee-may Chen, MD Director, Division of Gynecologic Oncology Professor Department of Obstetrics, Gynecology
More informationPathology Driving Decisions
Pathology Driving Decisions Part I: Understanding Your Diagnosis and Your Treatment Options May 7, 2018 Presented by: Dr. Matthew Mossanen completed his college and medical school training at UCLA. He
More informationGynecologic Oncology Overview Staging updates and Soap Box Issues
Gynecologic Oncology Overview Staging updates and Soap Box Issues Andrew. Green, M.D. Gynecologic Oncology Northeast Georgia Physician s Group Gainesville, GA 1 Overview 1) Review recent changes to FIGO/TNM
More informationCancer Conversations
Cancer Conversations Announcer: Welcome to Cancer Conversations, a podcast series from Dana-Farber Cancer Institute. In this Episode from July 2014, Dr. Huma Rana, Clinical Director of Dana-Farber s Center
More informationWelcome! Here s our agenda for today:
Welcome! Here s our agenda for today: What is ovarian cancer? What causes it? When does genetic testing come in? When are families at risk for ovarian cancer? What are the treatments? 3 things to remember
More informationNews from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O.
News from ASH: Updates on Lymphoma and Other Blood Cancers ASH Conference Coverage December 8, 2008 Andrew Evens, D.O. Please remember the opinions expressed on Patient Power are not necessarily the views
More informationCarrier Screening in your Practice Is it Time to Expand your View?
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/medical-industry-feature/carrier-screening-your-practice-it-time-expandyour-view/9648/
More informationSurgical Treatment For Pancreatic Cancer Webcast March 22, 2011 Venu Pillarisetty, M.D. Stan Barer. Introduction
Surgical Treatment For Pancreatic Cancer Webcast March 22, 2011 Venu Pillarisetty, M.D. Stan Barer Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer
More informationEpisode 93: What Role Stem Cells in Leukaemia?
Published on Up Close (https://upclose.unimelb.edu.au) Episode 93: What Role Stem Cells in Leukaemia? What Role Stem Cells in Leukaemia? VOICEOVER Welcome to Up Close, the research, opinion and analysis
More informationHello and welcome to Patient Power sponsored by UCSF Medical Center. I m Andrew Schorr.
The Integrated Approach to Treating Cancer Symptoms Webcast March 1, 2012 Michael Rabow, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center,
More informationUnderstanding Thyroid Cancer
Understanding Thyroid Cancer Recorded on: July 25, 2012 Christine Landry, M.D. Surgical Oncologist Banner MD Anderson Cancer Center Please remember the opinions expressed on Patient Power are not necessarily
More informationThe Treatment Landscape for Metastatic Breast Cancer Webcast Host: Andrew Schorr Guests: Hope Rugo, M.D. Robert Prosnitz, M.D.
The Treatment Landscape for Metastatic Breast Cancer Webcast Host: Andrew Schorr Guests: Hope Rugo, M.D. Robert Prosnitz, M.D. Dikla Benzeevi Please remember the opinions expressed on Patient Power are
More informationCervical Cancer. Introduction Cervical cancer is a very common cancer. Nearly one half million cases are diagnosed worldwide each year.
Cervical Cancer Introduction Cervical cancer is a very common cancer. Nearly one half million cases are diagnosed worldwide each year. Most cases of cervical cancer can be prevented by getting regular
More informationSee the latest estimates for new cases of ovarian cancer and deaths in the US and what research is currently being done.
About Ovarian Cancer Overview and Types If you have been diagnosed with ovarian cancer or are worried about it, you likely have a lot of questions. Learning some basics is a good place to start. What Is
More informationTRANSCRIPT. Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18
Do Corticosteroids Decrease the Pain of Acute Pharyngitis? - Frankly Speaking EP 18 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com.
More informationAfter Adrenal Cancer Treatment
After Adrenal Cancer Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. Lifestyle Changes After Treatment for Adrenal Cancer
More informationIntroduction. All Rights Reserved
Molecular Imaging for Breast Cancer: State-of-the-art Trials at SCCA Webcast October 8, 2008 David Mankoff, M.D., Ph.D. Hannah Linden, M.D. Erin Schubert Please remember the opinions expressed on Patient
More informationInformation leaflet for women with an increased lifetime risk of breast and ovarian cancer. Hereditary Breast and Ovarian Cancer (HBOC)
Information leaflet for women with an increased lifetime risk of breast and ovarian cancer Hereditary Breast and Ovarian Cancer (HBOC) What is Hereditary Breast and Ovarian Cancer (HBOC)? Hereditary Breast
More informationWhat is endometrial cancer?
Uterine cancer What is endometrial cancer? Endometrial cancer is the growth of abnormal cells in the lining of the uterus. The lining is called the endometrium. Endometrial cancer usually occurs in women
More informationClinical Trials: Non-Muscle Invasive Bladder Cancer. Tuesday, May 17th, Part II
Clinical Trials: Non-Muscle Invasive Bladder Cancer Tuesday, May 17th, 2016 Part II Presented by Yair Lotan, MD is holder of the Helen J. and Robert S. Strauss Professorship in Urology and Chief of Urologic
More informationPassport to Health Preventing and Recognizing Gynecologic Cancers
Passport to Health Preventing and Recognizing Gynecologic Cancers Presented by: Obstetrician/Gynecologist Leigh Bauer, M.D. They can sneak up on you. 2 Gynecologic cancers, that is. Knowing the facts can
More informationParkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. What is Parkinson s Disease?
Parkinson s Disease Webcast January 31, 2008 Jill Ostrem, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UCSF Medical Center, its medical staff or Patient
More informationTHE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES
THE MODERN GYNECOLOGIC EXAMINATION & SCREENING FOR GYNECOLOGIC MALIGNANCIES Denise Uyar, MD Associate Professor OB/GYN Chief Gynecologic Oncology Medical College of Wisconsin April 12, 2019 NO DISCLOSURES
More informationASCO 2016: Ask the Lung Cancer Experts
Live @ ASCO 2016: Ask the Lung Cancer Experts Charu Aggarwal, MD, MPH Assistant Professor of Medicine University of Pennsylvania Health System Liza Villaruz, MD Hematology/Oncology Specialist University
More informationA Timely Decision A STORY ABOUT FACING BARRIERS IN ORDERTO PREVENT CERVICAL CANCER
A Timely Decision A STORY ABOUT FACING BARRIERS IN ORDERTO PREVENT CERVICAL CANCER STARRING MARY Prof. YAYA LOLI BLANCA JULIA 1 Mary, Loli y Julia are friends who meet during English classes held at a
More informationContraception: The Pill Needs to Share (or Move Over) Frankly Speaking EP 17
Contraception: The Pill Needs to Share (or Move Over) Frankly Speaking EP 17 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional
More informationPresented by: Support Connection, Inc. (*With funding from The HERA Women's Cancer Foundation
Ovarian Cancer Teleconference Sept. 25, 2013- Page 1 Program Title: Toll-Free Educational Teleconference for Women with Ovarian Cancer 2013 Presented by: Support Connection, Inc. (*With funding from The
More informationClinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer
Clinical Trials: Advanced or Metastatic Bladder Cancer Wednesday June 22 nd, 2016 Part III: Question and Answer Questions Answered by Andrea Apolo, MD is a Lasker Clinical Research Scholar and tenure-track
More informationOvarian Cancer. What you should know. making cancer less frightening by enlightening
Ovarian Cancer What you should know making cancer less frightening by enlightening ovarian cancer the facts Over 360 cases are diagnosed in Ireland annually It is the 6th most common cancer in women 4
More informationMycoplasma Genitalium: Get to Know the Hidden STI
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/womens-health-update/mycoplasma-genitalium-get-to-know-hiddensti/9501/
More informationRobotic Surgery: A Better Option for Many Head & Neck Cancers
Robotic Surgery: A Better Option for Many Head & Neck Cancers Neal Futran, MD, DMD Director of Head and Neck Surgery, Department of Otolaryngology UW Medicine Eduardo Mendez, MD Assistant Professor, Otolaryngology:
More informationAdvances in the Treatment of Colorectal Cancer Webcast February 17, 2009 Cathy Eng, M.D. Introduction
Advances in the Treatment of Colorectal Cancer Webcast February 17, 2009 Cathy Eng, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of M. D. Anderson Cancer Center,
More informationExpert Tips for Diagnosis and Management of Bacterial Vaginosis
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/miscellaneous/whats-new-bacterial-vaginosis/expert-tips-for-diagnosismanagement-of-bacterial-vaginosis/9894/
More informationNon Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options. Part II: The Future Treatment of NMIBC
Non Muscle Invasive Bladder Cancer (NMIBC) Experts Discuss Treatment Options Wednesday, June 14, 2017 Part II: The Future Treatment of NMIBC Presented by Dr. Arlene Siefer-Radtke is an Associate Professor
More informationUpper Tract Urothelial Carcinomas (UTUCs)
Upper Tract Urothelial Carcinomas (UTUCs) Part II: UTUC Treatment Options November 14, 2017 Moderated by: Presented by: Gary D. Steinberg, MD University of Chicago Medical Center Ahmad Shabsigh, MD Ohio
More informationSo bowel cramps, bladder cramps, pelvic or lower abdominal discomfort, but if it happens everyday for 2 weeks, then people should be more concerned.
1 Support for Yale Cancer Answers is provided by AstraZeneca, proud partner in personalized medicine, developing tailored-treatment for cancer patients. Learn more at astrazeneca-us.com Welcome to Yale
More informationPlease Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222.
Announcer: Please Understand Me, Managing ADHD within a Marriage, this is Stay Happily Married episode number 222. Welcome to Stay Happily Married, your source for weekly updates on the latest tips and
More informationPublic Health Live! Breast Density and Breast Cancer Risk, December 20, 2018 Transcript
Public Health Live! Breast Density and Breast Cancer Risk, December 20, 2018 Transcript Moderator Rachel Breidster: Hello and welcome to Public Health Live! I m Rachel Breidster and I ll be your moderator
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationPap Test. F r e q u e n t l y A s k e d Q u e s t i o n s
Pap Test Q: What is a Pap test? A: The Pap test, also called a Pap smear, checks for changes in the cells of your cervix. The cervix is the lower part of the uterus (womb) that opens into the vagina (birth
More informationAndrew Schorr: What treatment have you had, Gaye, then in that interim four years? What's happened?
Navigating Sarcoma Treatments Health Radio June 20, 2007 Christopher Ryan, M.D. Kevin Norwood, M.D. Angela Lim, LICSW, OSW-C Gaye Johnson Please remember the opinions expressed on Patient Power are not
More informationExpert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Introduction
Expert Tips to Stop Smoking Now Webcast January 17, 2011 Vicky Fang, M.D. Yunyu Cao, M.D. Please remember the opinions expressed on Patient Power are not necessarily the views of UW Medicine, their staff,
More informationHello and welcome to Patient Power sponsored by the Seattle Cancer Care Alliance. I'm Andrew Schorr.
New Hope For Melanoma Webcast April 6, 2011 Kim Margolin, M.D. David Byrd, M.D. Kathy Sparks Please remember the opinions expressed on Patient Power are not necessarily the views of Seattle Cancer Care
More informationAn Update on BioMarin Clinical Research and Studies in the PKU Community
An Update on BioMarin Clinical Research and Studies in the PKU Community Barbara Burton, MD, Professor of Pediatrics, Northwestern University Feinberg School of Medicine, Director of PKU Clinic, Children
More informationCombining Individualized Treatment Options with Patient-Clinician Dialogue
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationIntroduction. All Rights Reserved
Unique Treatment Approaches For Thyroid and Endocrine Cancers Webcast February 25, 2009 David Mankoff, M.D., Ph.D.; Peter Capell, M.D.; Sarah Javid, M.D. Natalie Boisseau; Kim Valdez Please remember the
More informationUNDERSTANDING SQUAMOUS CELL LUNG CANCER
UNDERSTANDING SQUAMOUS CELL LUNG CANCER A guide for patients and caregivers FREE TO BREATHE SUPPORT LINE (844) 835-4325 A FREE resource for lung cancer patients & caregivers About this brochure This brochure
More informationAfter Soft Tissue Sarcoma Treatment
After Soft Tissue Sarcoma Treatment Living as a Cancer Survivor For many people, cancer treatment often raises questions about next steps as a survivor. What Happens After Treatment for Soft Tissue Sarcomas?
More informationLung Cancer Awareness Month Update 2008
Lung Cancer Awareness Month Update 2008 Guest Expert: Frank, MD Professor of Thoracic Surgery Lynn, MD Professor of Pulmonary Medicine www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationThe HPV Vaccine: Not Just for Young Girls and Teens
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-womens-health/the-hpv-vaccine-not-just-for-young-girlsand-teens/3497/
More informationMalignant Gliomas: Understanding Brain Tumors Webcast June 18, 2008 Daniel Silbergeld, M.D. Cynthia Cottle-Bailess, R.N.
Malignant Gliomas: Understanding Brain Tumors Webcast June 18, 2008 Daniel Silbergeld, M.D. Cynthia Cottle-Bailess, R.N. Please remember the opinions expressed on Patient Power are not necessarily the
More informationAiming for a CLL Treatment Home Run Recorded on June 1, 2014
Patient Power Knowledge. Confidence. Hope. Aiming for a CLL Treatment Home Run Recorded on June 1, 2014 Thomas Kipps, MD, PhD Deputy Director of Research Operations UC San Diego Moores Cancer Center Please
More informationAs a Lung Cancer Patient, What Information Do I Need to Make the Best Choices?
As a Lung Cancer Patient, What Information Do I Need to Make the Best Choices? Mary Ellen Hand, RN, BSN Nurse Coordinator Rush University Medical Center Emma Shtivelman, PhD Chief Scientist Cancer Commons
More informationDiabetes Remission with Weight Loss - Frankly Speaking EP 49
Diabetes Remission with Weight Loss - Frankly Speaking EP 49 Transcript Details This is a transcript of an episode from the podcast series Frankly Speaking accessible at Pri- Med.com. Additional media
More informationAndrew Schorr: Dr. Young, for patients receiving initial treatment could you discuss the findings comparing horse ATG and rabbit ATG?
What s New in Aplastic Anemia Treatment American Society of Hematology Meeting December 2011 Dr. Neal S. Young Please remember the opinions expressed on Patient Power are not necessarily the views of our
More information